NRx Pharmaceuticals, Inc. (NRXP): Price and Financial Metrics
GET POWR RATINGS... FREE!
NRXP Stock Price Chart Interactive Chart >
NRXP Price/Volume Stats
| Current price | $0.53 | 52-week high | $26.24 |
| Prev. close | $0.58 | 52-week low | $0.49 |
| Day low | $0.51 | Volume | 2,985,100 |
| Day high | $0.58 | Avg. volume | 930,289 |
| 50-day MA | $1.93 | Dividend yield | N/A |
| 200-day MA | $5.76 | Market Cap | 35.63M |
NRx Pharmaceuticals, Inc. (NRXP) Company Bio
NRX Pharmaceuticals, Inc. is a clinical stage pharmaceutical company. The Company specializes in researching investigational medicines and is engaged in the development of medicines and vaccines for Covid-19, other respiratory conditions, suicidal depression, and PTSD.
Latest NRXP News From Around the Web
Below are the latest news stories about NRX Pharmaceuticals Inc that investors may wish to consider to help them evaluate NRXP as an investment opportunity.
How Much Of NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Do Insiders Own?Every investor in NRx Pharmaceuticals, Inc. ( NASDAQ:NRXP ) should be aware of the most powerful shareholder groups... |
NRx Pharmaceuticals Announces US National Institutes of Health Study of ZYESAMI® (aviptadil) in Critical COVID-19 is Cleared to Complete Full EnrollmentNRx Pharmaceuticals (Nasdaq: NRXP), a clinical-stage, biopharmaceutical company, today announced results of a review conducted by the Therapeutics and Prevention Data Safety and Monitoring Board (DSMB) of the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) on February 14, 2022. The DSMB reviewed data on 448 ICU patients with Critical COVID-19 Respiratory Failure who were enrolled in the ACTIV-3b (TESICO) trial1. The TESICO protocol was sub |
NRx Reports Remarks by Israel Institute for Biological Research on the future of the BriLife™ Covid-19 Investigational VaccineRemarks by Dr. Shmuel Yitzhaki, as published in Globes, an Israeli business newspaperBriLife vaccine may have better neurtralizing ability against Omicron variant than first generation mRNA vaccines, according to IIBR findings RADNOR, Pa., Feb. 11, 2022 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals (Nasdaq: NRXP), a clinical-stage, biopharmaceutical company, today reported remarks by Dr. Shmuel Yitzhaki, Director of the Israel Institute for Biological Research, who spoke at the Eli Hurvitz Institute f |
NRx Pharmaceuticals Announces Closing of $25 Million Private Placement Priced at a Premium to Market Under Nasdaq RulesNRx Pharmaceuticals (NRx) (Nasdaq: NRXP (or the "Company"), a Delaware corporation, today announced that it has closed its previously announced private placement priced at a premium to market under Nasdaq rules of 7,824,727 shares of its common stock and unregistered preferred investment options (the "investment options") to purchase up to an aggregate of 7,824,727 shares of common stock. The purchase price for one share of common stock and one investment option to purchase one share of common s |
NRx Pharmaceuticals Announces $25 Million Private Placement Priced at a Premium to Market under Nasdaq RulesNRx Pharmaceuticals (NRx) (Nasdaq: NRXP) (or the "Company"), a Delaware corporation, today announced that it has entered into definitive agreements with investors to purchase 7,824,727 shares of common stock in a private placement priced at a premium to market under Nasdaq rules. The Company will also issue to the investors unregistered preferred investment options (the "investment options") to purchase up to an aggregate of 7,824,727 shares of common stock. The purchase price for one share of c |
NRXP Price Returns
| 1-mo | -66.03% |
| 3-mo | -82.27% |
| 6-mo | -92.07% |
| 1-year | -97.59% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -88.91% |
| 2021 | -80.41% |
| 2020 | 130.19% |
| 2019 | 3.92% |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...